Core Viewpoint - Sangfor Technologies (三生国健) announced that its shareholder, Dajia International (达佳国际), plans to reduce its holdings by up to 6.1679 million shares, representing no more than 1% of the company's total share capital, due to personal funding needs [1] Summary by Relevant Sections - **Shareholding Details** - Dajia International currently holds 25.1607 million shares of Sangfor Technologies, accounting for 4.08% of the company's total share capital [1]

Core Viewpoint - The controlling shareholder and concerted action party of the company, Dajia International (Hong Kong) Limited, plans to reduce its stake in the company by up to 6.1679 million shares, representing no more than 1% of the total share capital, due to personal funding needs [1] Summary by Relevant Sections - **Share Reduction Plan** - The share reduction will occur between December 1, 2025, and February 28, 2026 [1] - The reduction will be executed through centralized bidding [1] - There is no set price range for the share reduction [1]

Core Viewpoint - Dajia International (Hong Kong) Limited, a shareholder with a 4.08% stake in Sangfor Technologies (688336), plans to reduce its holdings by up to 6.1679 million shares, representing no more than 1% of the company's total share capital [1] Group 1 - Dajia International intends to sell shares through a centralized bidding process [1] - The total number of shares to be reduced is capped at 6.1679 million [1] - The reduction will not exceed 1% of the company's total equity [1]

Core Viewpoint - Dajia International (Hong Kong) Limited plans to reduce its stake in Sanofi Health by selling up to 6.1679 million shares, representing 1.00% of the company's total share capital, due to funding needs [1] Summary by Sections - Shareholding Information - As of the announcement date, Dajia International holds 25.1607 million shares, accounting for 4.08% of the company [1] - The shares were acquired before the IPO and will be tradable starting from July 22, 2024 [1] - Planned Share Reduction - Dajia International intends to sell shares through a centralized bidding method between December 1, 2025, and February 28, 2026 [1] - The maximum number of shares to be sold is 6.1679 million [1]

证券代码：688336 证券简称：三生国健 公告编号：2025-062 三生国健药业（上海）股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 截至本公告披露日，达佳国际（香港）有限公司（以下简称"达 佳国际"）持有三生国健药业（上海）股份有限公司（以下简称"三 生国健"或"公司"）股份 25,160,657 股，占公司目前总股本的 4.08%。 以上股份为公司首次公开发行前取得的股份，已于 2024 年 7 月 22 日 起上市流通。 减持计划的主要内容 根据股东自身资金需求，达佳国际拟在本次减持计划公告之日起 15 个交易日后的三个月内，以集中竞价方式择机减持其所持公司股 份合计不超过 6,167,857 股，即不超过公司总股本的 1.00%。 若减持计划期间公司有送股、资本公积转增股本、配股等股份变 动事项，上述拟减持比例不变，股份数量将相应进行调整。 一、减持主体的基本情况 | | | 1 | | 股东名称 | 持有数量 | 持有比 | ...

Core Viewpoint - Dajia International (Hong Kong) Limited plans to reduce its holdings in Sanofi Health by up to 6.17 million shares, representing no more than 1.00% of the company's total share capital, due to its own funding needs [1] Group 1 - The share reduction will occur between December 1, 2025, and February 28, 2026 [1] - The shares to be sold are from the company's pre-initial public offering holdings [1] - The reduction will not change the company's controlling shareholder or actual controller, nor will it significantly impact the company's ongoing operations [1]

Core Viewpoint - Sanofi Guojian (688336.SH) announced that its shareholder, Dajia International, plans to reduce its holdings by up to 6.1679 million shares, representing no more than 1% of the company's total share capital, within three months after the announcement of the reduction plan [1] Summary by Category - **Shareholder Action** - Dajia International intends to reduce its stake in Sanofi Guojian through centralized bidding [1] - The reduction will occur within three months following the announcement, starting 15 trading days after the announcement [1] - **Shareholding Details** - The total number of shares to be reduced is capped at 6.1679 million [1] - This reduction accounts for a maximum of 1% of the company's total share capital [1]

Core Viewpoint - Sanofi International plans to reduce its stake in Sangfor Technologies (688336.SH) by selling up to 6.1679 million shares, which represents no more than 1% of the company's total share capital, within three months after the announcement of the reduction plan [1] Summary by Categories - **Share Reduction Plan** - Sanofi International intends to sell a maximum of 6.1679 million shares of Sangfor Technologies [1] - The share reduction will be executed through centralized bidding [1] - The selling period is set for three months starting from 15 trading days after the announcement [1]

Market Overview - The three major stock indices collectively declined today, with over 2100 stocks closing higher, including 64 stocks hitting the daily limit up [1] - For the week, all three indices saw slight increases: Shanghai Composite Index rose by 1.08%, Shenzhen Component Index increased by 0.19%, and ChiNext Index gained 0.65% [1] Historical Highs - A total of 41 stocks reached historical closing highs today, excluding newly listed stocks from the past year [1] - The sectors with the most stocks hitting historical highs included power equipment (9 stocks), electronics (8 stocks), and basic chemicals (5 stocks) [1] - The average increase for stocks that reached historical highs was 4.98%, with notable gainers including Sanxiang New Materials and Guoen Co., Ltd. [1] Weekly Performance - Over 2900 stocks rose this week, with 28 stocks increasing by over 30% [4] - The top performer was Zhongneng Electric, which surged by 78.37%, followed by Huasheng Lithium and Hefei China, both exceeding 61% [4] Institutional Activity - Institutions were active in the market, with 15 stocks seeing significant net purchases exceeding 100 million yuan [9] - The stock with the highest net purchase was Duofluor, which rose by 13.03% and had a turnover rate of 95.38% [9] - Other notable stocks with high institutional net purchases included Altes and Changsheng Lithium [10] Notable Stocks - The top gainers for the week included Zhongneng Electric (78.37%), Jiangsheng Lithium (61.16%), and Hefei China (61.08%) [5] - Conversely, stocks like Huide Technology and Qingyue Technology saw significant declines, with Huide Technology dropping by 24.78% [7] Regulatory Actions - The Shenzhen Stock Exchange is monitoring stocks with significant price fluctuations, including "*ST Dongyi" and "ST Zhongdi" [15] - Several companies, including ST Chang Pharmaceutical and Aiyou Steel, are under investigation for alleged violations of information disclosure regulations [16][17]

Group 1 - The restructuring protein concept declined by 1.06%, ranking among the top declines in concept sectors, with *ST WanFang hitting the limit down [1] - Within the restructuring protein sector, major declines were seen in He Yuan Bio, San Sheng Guo Jian, and Hua Xi Bio, while 15 stocks experienced price increases, with InnoTech, Dezheng Health, and Ao Pu Mai leading the gains at 1.72%, 1.36%, and 1.33% respectively [1][2] Group 2 - The restructuring protein sector saw a net outflow of 542 million yuan from main funds, with 33 stocks experiencing outflows, and 13 stocks seeing outflows exceeding 10 million yuan [2] - He Yuan Bio had the highest net outflow of 277 million yuan, followed by Rejing Bio, Hua Xi Bio, and Hua Lan Bio with net outflows of 38.27 million yuan, 34.39 million yuan, and 32.92 million yuan respectively [2][3] Group 3 - The top stocks with net inflows in the restructuring protein sector included Jianyou Co., Xilong Science, and Borui Pharmaceutical, with net inflows of 17.18 million yuan, 13.67 million yuan, and 8.93 million yuan respectively [4]